Managing the acute coronary syndrome patient: Evidence based recommendations for anti-platelet therapy

Area of Science:

• Cardiology
• Pharmacology

Background:

• Acute coronary syndrome (ACS) requires multidisciplinary team management.
• Primary care physicians, PAs, NPs, and pharmacists are crucial in ACS care.
• Recent guideline updates focus on managing unstable angina (UA)/non ST-segment elevation ACS (NSTE-ACS) and ST-segment elevation myocardial infarction (STEMI).

Purpose of the Study:

• To summarize recent guideline updates for ACS management.
• To focus on recommendations for antiplatelet therapy.
• To highlight the role of P2Y12 inhibitors in specific clinical scenarios.

Main Methods:

• Review of updated American College of Cardiology Foundation/American Heart Association guidelines.
• Focus on antiplatelet therapy recommendations.
• Discussion of P2Y12 inhibitor utilization in NSTE-ACS and STEMI.

Main Results:

• Dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) is recommended for NSTE-ACS and STEMI patients.
• This therapy is advised both during and after reperfusion.
• Guidelines offer specific recommendations for P2Y12 inhibitor use in various situations.

Conclusions:

• Healthcare teams must be familiar with the latest ACS guidelines.
• Patient education on risk reduction and medication adherence is vital.
• Updated guidelines support optimal management of ACS patients through evidence-based antiplatelet strategies.